PF-514273
Bicyclic lactam CB1 antagonist (Ki 1.0 nM), designed by Pfizer for weight management and advanced to clinical trials.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₁H₁₇Cl₂F₂N₃O₂
CAS 851728-60-4
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 452.30 g/mol
Updated on
In plain terms
PF-514273 is a laboratory molecule that blocks the CB1 receptor, the one cannabis activates. Pfizer developed it in 2009 as a drug candidate for weight management and advanced it to trials in humans; it was never marketed. It is now used as a research tool in animals.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to PF-514273: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PF-514273.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AntagonistKi = 1 nM · human83 out of 100
Dow et al., J Med Chem 2009: discovery of PF-514273, a bicyclic lactam CB1 receptor antagonist (numerical values read in ChEMBL, document CHEMBL1138462) (new tab) · binding affinity at human CB1 (value read in ChEMBL, Dow 2009); functional antagonism Ki 0.82 nM (CHO-K1, response to CP-55,940)
- CB2Binding (function not established)no measured value cited
Ki greater than 10 000 nM at human CB2 (value read in ChEMBL, Dow 2009): no measurable affinity
Pharmacology
PF-514273 belongs to the second wave of CB1 receptor antagonists developed for weight management. Dow and colleagues (2009) describe a series of bicyclic lactams, in which molecule 19d, or PF-514273, was selected for its potency and selectivity as a CB1 antagonist and for its oral activity on food intake in rodents; it was advanced to clinical trials in humans. The ChEMBL values for this article give a Ki of 1.0 nM at human CB1 against more than 10,000 nM at CB2, a selectivity of at least 10,000-fold. In rats, oral bioavailability is 42 % and half-life 3.5 hours, with a steady-state brain/plasma ratio of 3.1 (same sources). The context of the class weighed on what followed: rimonabant, authorised in the European Union in June 2006, had its authorisation recommended for suspension by the CHMP on 23 October 2008, with a risk of psychiatric disorders approximately doubled compared with placebo (EMA), and Janero and Makriyannis (2009) report the suspension of the development programmes of rimonabant, taranabant and otenabant. The outcome of the clinical development of PF-514273 is not reported in the sources consulted. The molecule later served as a pharmacological tool (Pina and Cunningham 2014).
Key sources.
- Dow et al., J Med Chem 2009: discovery of PF-514273, a bicyclic lactam CB1 receptor antagonist (numerical values read in ChEMBL, document CHEMBL1138462) (new tab)PMID 19351113
- Pina and Cunningham, Alcohol 2014: effects of PF 514273 on the acquisition and expression of ethanol conditioned place preference (new tab)PMID 24954022
- Janero and Makriyannis, Expert Opin Emerg Drugs 2009: cannabinoid receptor antagonists, clinical experience and translational prognosis (new tab)PMID 19249987
- EMA, 23 October 2008: the European Medicines Agency recommends suspension of the marketing authorisation for Acomplia (rimonabant) (new tab)
- PubChem, PF-514273, CID 11316919 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It was produced in a Pfizer pharmaceutical development programme and was not marketed (no marketing authorisation found).
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It is a bicyclic lactam, a 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (name given in the title of Dow et al. 2009).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No marketing authorisation was found.
- France
Not classified: PF-514273 does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (a bicyclic lactam with pyrazole and oxazepinone rings) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Dow et al., J Med Chem 2009: discovery of PF-514273, a bicyclic lactam CB1 receptor antagonist (numerical values read in ChEMBL, document CHEMBL1138462) (new tab)PMID 19351113
- Pina and Cunningham, Alcohol 2014: effects of PF 514273 on the acquisition and expression of ethanol conditioned place preference (new tab)PMID 24954022
- Janero and Makriyannis, Expert Opin Emerg Drugs 2009: cannabinoid receptor antagonists, clinical experience and translational prognosis (new tab)PMID 19249987
- EMA, 23 October 2008: the European Medicines Agency recommends suspension of the marketing authorisation for Acomplia (rimonabant) (new tab)
- PubChem, PF-514273, CID 11316919 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- IUPAC name
- 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one
- Other names
- PF 514273 · PF 0514273 · PF514273
Identifiers
- Formula
- C₂₁H₁₇Cl₂F₂N₃O₂
- CAS
- 851728-60-4
- PubChem CID
- 11316919(new tab)
- InChIKey
- FJMQJSUOOGOWBD-UHFFFAOYSA-N
- SMILES
- CC(CN1CCOC2=
C(N(N= C2C1= O) C3= CC= CC= C3Cl) C4= CC= C(C= C4) Cl) (F) F
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.